



LKT Laboratories, Inc.

Linagliptin

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID L337521

CAS No. 668270-12-0

Chemical Name 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione

Synonym Tradjenta, BI 1356, Ondero

Formula C₂₅H₂₈N₈O₂

Formula Wt. 472.55

Melting Point


Purity ≥98%

Solubility Soluble in DMSO (17 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (1 mg/ml at 25 °C), 0.5% hydroxyethylcellulose (30 mg/ml at 25 °C), and methanol.

Store Temp -20 °C

Ship Temp Ambient

Description Linagliptin is a dipeptidyl peptidase 4 inhibitor glucose-lowering compound with low risk of inducing hypoglycaemia. It has been found that linagliptin may modify several measures of microvascular function including hyperaemia area, resting blood flow, and peak blood flow in the fasting state. Treatment of STZ-diabetic Wistar rats was shown to decrease levels of oxidative stress, protect against microvascular damage, enhance neuronal cell survival, and prevent vasoregression. Furthermore, treatment was found to decrease aortic pulse wave velocity, glycated haemoglobin, fasting plasma glucose, and triglycerides in people with early type 2 diabetes. Contrarily, linagliptin has also been known to cause adverse reactions such as ulcers and blisters.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
L337521	5 mg	\$45.30
L337521	10 mg	\$60.10
L337521	25 mg	\$105.30
L337521	50 mg	\$180.30

References Jax T, Stirban A, Terjung A, et al. A randomized, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. *Cardiovasc Diabetol*. 2017 Jan 21;16(1):13. PMID: 28109295.

Dietrich N, Kolibabka M, Busch S, et al. The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy. *PLoS One*. 2016 Dec 12;11(12):e0167853. PMID: 27942008.

de Boer SA, Heerspink HJL, Juarez Orozco LE, et al. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE). *Diabetes Obes Metab*. 2017 Aug;19(8):1147-1154. PMID: 28244635.

Psomadakis C, Shahzad N, Katz J. Linagliptin-associated blistering and ulceration. *BMJ Case Rep*. 2017 May 31;2017. PMID: 28566414.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.